Cancer Epidemiology最新文献

{"title":"Cancer survival in Italian patients diagnosed between 2008 and 2017","authors":"Riccardo Capocaccia ,&nbsp;Mario Fusco ,&nbsp;Maurizio Zarcone ,&nbsp;Santo Fruscione ,&nbsp;Maria Teresa Pesce ,&nbsp;Fabrizio Stracci ,&nbsp;Walter Mazzucco ,&nbsp;AIRTUM Working Group,&nbsp;Giorgio Graziano ,&nbsp;Sergio Mazzola ,&nbsp;Antonietta Minichino ,&nbsp;Alessandra Sessa ,&nbsp;Rosario Tumino ,&nbsp;Antonino Ziino Colanino ,&nbsp;Giuseppa Candela ,&nbsp;Ilaria Loperto ,&nbsp;Francesca Vitale ,&nbsp;Rossella Abbate ,&nbsp;Santa Valenti Clemente ,&nbsp;Romina Vincenzi ,&nbsp;Giuseppe Sampietro","doi":"10.1016/j.canep.2026.103001","DOIUrl":"10.1016/j.canep.2026.103001","url":null,"abstract":"<div><div>As national cancer survival estimates in Italy date back to 2011, we provided updated figures using population-based cancer registries. Analyses by age and sex included 1.418.044 cancers diagnosed between 2013 and 2017 from 34 registries covering 48 million residents. The 2008–2017 period, with 20 registries covering 24 million residents, was used for trends and regional comparisons. Net survival was estimated by Pohar-Perme method with life tables by year, sex, residence and calculated using the international standard distribution. Five-year age-standardized net survival for all cancers combined was 66.7 % in females and 62.2 % in males. Females had better survival than males for most cancers, notably acute lymphatic leukaemia (+9 % points (pp)), upper respiratory/digestive (+9 pp), lung (+6 pp), CNS (+5 pp), and stomach (+4 pp). Males had a higher survival for bladder (+4 pp), kidney (+2 pp), and urinary cancers (+5 pp). Best outcomes (&gt;75 %) were documented for prostate, testicular, breast, endometrial, thyroid, melanoma, Hodgkin lymphoma, bladder, and chronic lymphatic leukaemia. Poorest prognosis (&lt;30 %) was for CNS, liver, lung, pancreas, and acute myeloid leukaemias. Survival was age-dependent, highest in younger and lowest in older patients, with &gt; 40 % points gaps in some haematological cancers. From 2008–2017, net survival arose from 65.7 % to 70.7 % in men and from 69.9 % to 74.1 % in women. Improvements were seen for pancreas, lung, and acute leukaemias, mainly in women, while decreases affected bladder, cervical, chronic lymphatic leukaemia in men. Geographical disparities persisted, with higher survival in Northern-Central Italy (64.0 % for men and 68.3 % for women) than in Southern-Islands (58.1 % for men and 63.7 %, for women). Our findings confirmed a better prognosis for younger patients and females than male patients. Survival has continued to improve over time, even at a higher improving rate in the considered period than the past.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"101 ","pages":"Article 103001"},"PeriodicalIF":2.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146138002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring associations between travel burden, clinical features, and outcomes from head and neck cancer in Scotland, UK","authors":"Melanie Turner ,&nbsp;Samuel Kent ,&nbsp;Sharon Hanley ,&nbsp;Peter Murchie","doi":"10.1016/j.canep.2026.103012","DOIUrl":"10.1016/j.canep.2026.103012","url":null,"abstract":"<div><h3>Background</h3><div>Geographic inequalities in cancer outcomes are reported internationally, but little is known about associations between geography and head and neck cancer (HNC) in Scotland. We explored how travelling times to health services influences clinical characteristics, stage at diagnosis, treatment, and one-year mortality for HNC in Scotland.</div></div><div><h3>Methods</h3><div>We conducted a national, population-based, retrospective cohort study using linked administrative and clinical data covering all individuals diagnosed with HNC in Scotland between 2014 and 2019. We calculated and categorised their travelling times to key healthcare facilities and explored associations with key outcomes - HPV-status, stage at diagnosis, treatment received, and one-year mortality. Multivariable regression models adjusted for key confounders.</div></div><div><h3>Results</h3><div>6692 patients were included. Patients with the longest travelling time (≥ 60 min or island) were less likely to present with advanced-stage disease (OR 0.73, 95 % CI: 0.54–0.98) and were significantly less likely to die within one year (HR 0.64, 95 % CI: 0.46–0.88). No difference was observed in proportion of HPV-positive cancers across travel time categories. There were also no significant differences in proportions receiving surgery or treated within 31 days of diagnosis.</div></div><div><h3>Conclusions</h3><div>The association between geography and HNC in Scotland is complex and differs from previous studies in other cancers. Patients with the longest travel time had lower risk of advanced stage at presentation and reduced one-year mortality with no apparent difference in HPV-prevalence or treatment access. In context these findings suggest that travelling time disadvantage is not uniform across cancer types and highlights the need for cancer site–specific approaches to monitoring and reducing inequalities. This large, population-based analysis provides the most comprehensive assessment of HNC and geography in Scotland to date. Findings challenge assumptions of consistent travel time disadvantage and can inform policy on equitable cancer care delivery in the pre-pandemic era.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"101 ","pages":"Article 103012"},"PeriodicalIF":2.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146173802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prostate cancer in Korea: Nationwide trends in prevalence and medication use during 2011–2021","authors":"Jaehee Jung ,&nbsp;Hyunha Kang ,&nbsp;Eunjung Choo ,&nbsp;Hye-Young Kang ,&nbsp;Chang Wook Jeong ,&nbsp;Ha-Lim Jeon ,&nbsp;Hankil Lee","doi":"10.1016/j.canep.2026.102987","DOIUrl":"10.1016/j.canep.2026.102987","url":null,"abstract":"<div><h3>Introduction</h3><div>The incidence of prostate cancer (PC) is rapidly increasing with population aging. With the emergence of new androgen receptor-targeting agents beyond androgen deprivation therapy, the treatment paradigm for PC is expected to shift. This study aimed to analyze the epidemiological characteristics and treatment patterns of patients with PC in Korea over the past decade, with a particular focus on drug utilization.</div></div><div><h3>Materials and methods</h3><div>We conducted a prevalence-based cross-sectional study on all Korean patients who received medical care for PC between 2011 and 2021. Patient characteristics, including age, comorbidities, metastatic status, drug classes, and treatment patterns, were analyzed.</div></div><div><h3>Results</h3><div>In 2021, the prevalence of PC was 532 per 100,000 adult men, an increase of 170.45 %, from 220 per 100,000 adult men in 2011. The mean age of patients with PC in 2021 was 73.07 years, with more than 80 % aged 65 years or older. Comorbidities, such as diabetes, pulmonary diseases, and mild liver disease, were common. Androgen deprivation therapy remained the most common pharmacological treatment; however, the proportion of its use gradually decreased over time, and the introduction of androgen receptor-targeting agents led to a steady increase in their use.</div></div><div><h3>Conclusions</h3><div>This study provides real-world evidence of the epidemiology and therapeutic patterns of PC, thereby enhancing the understanding of the current clinical landscape in Korea.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"101 ","pages":"Article 102987"},"PeriodicalIF":2.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145981928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Determinants of colonoscopy adherence after positive colorectal cancer screening: Insights from individual and municipality-level data in Flanders","authors":"Thao Linh Ha ,&nbsp;Thuy Ngan Tran ,&nbsp;Sarah Hoeck ,&nbsp;Guido Van Hal","doi":"10.1016/j.canep.2026.103011","DOIUrl":"10.1016/j.canep.2026.103011","url":null,"abstract":"<div><h3>Background</h3><div>Timely follow-up colonoscopy after a positive fecal immunochemical test (FIT) is essential for the effectiveness of colorectal cancer (CRC) screening programs (CRC-SP). However, a substantial proportion of individuals fail to complete diagnostic follow-up. This study aimed to identify individual- and municipality-level factors associated with nonadherence to follow-up colonoscopy in the Flemish CRC-SP.</div></div><div><h3>Methods</h3><div>Individual-level data from the Flemish Centre for Cancer Detection (CCD), including 26,539 individuals with a positive FIT result in 2019, were linked with publicly available municipality-level indicators to assess demographic, socioeconomic, and healthcare-related characteristics. The outcome was nonadherence to follow-up colonoscopy within one year after a positive FIT result. A multivariable logistic regression model was developed using a structured approach: univariable screening (p &lt; 0.15), multicollinearity assessment, and variable selection using least absolute shrinkage and selection operator (LASSO) regression. A random intercept for province was incorporated to account for potential clustering.</div></div><div><h3>Results</h3><div>A total of 5021 individuals (18.9 %) did not complete a follow-up colonoscopy within one year after a positive FIT result. In the final multivariable model, older age (65–69: OR = 1.12, 95 % CI: 1.03–1.21, p = 0.006; 70–74: OR = 1.29, 95 % CI: 1.20–1.40, p &lt; 0.001), male gender (OR = 1.14, 95 % CI: 1.07–1.22, p &lt; 0.001), and higher proportions of individuals living alone (OR = 1.02, 95 % CI: 1.00–1.03, p = 0.009) was associated with increased odds of nonadherence. In contrast, having a global medical dossier (GMD) were associated with better adherence (OR = 0.97, 95 % CI = 0.96–0.98, p &lt; 0.001). Variance at the provincial level was negligible.</div></div><div><h3>Conclusions</h3><div>This study provides evidence to support targeted implementation strategies within the Flemish CRC-SP. Strengthening primary care involvement and addressing social determinants of health may improve follow-up colonoscopy rates and enhance the equity and effectiveness of the screening program.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"101 ","pages":"Article 103011"},"PeriodicalIF":2.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146080033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in use of poly (ADP-ribose) polymerase inhibitor (PARPi) in ovarian cancer","authors":"Joseph A. Dottino ,&nbsp;Katherine E. Baumann ,&nbsp;Katharine M. Esselen ,&nbsp;Rebecca Costa ,&nbsp;Stephanie Argetsinger ,&nbsp;Dennis Ross-Degnan ,&nbsp;Anita K. Wagner","doi":"10.1016/j.canep.2026.102996","DOIUrl":"10.1016/j.canep.2026.102996","url":null,"abstract":"<div><h3>Background</h3><div>To assess population-level trends in use of poly (ADP-ribose) polymerase inhibitors (PARPis) among ovarian cancer patients in the years following initial FDA approvals.</div></div><div><h3>Methods</h3><div>A national, commercial and Medicare Advantage insurance claims database was used to identify patients with ovarian cancer from 2015 to 2021. Year of ovarian cancer diagnosis was categorized by initial period of PARPi approval for treatment indication (2015–2016) and expanded period of PARPi approval for treatment and maintenance indications (2017–2021). Clinical and demographic characteristics were assessed. The primary outcome was proportion of patients with PARPi dispensings. Time from first observed ovarian cancer diagnosis to first observed PARPi dispensing was calculated.</div></div><div><h3>Results</h3><div>Of 23,165 patients with ovarian cancer, most were 65 years or older (62.8 %) and had Medicare Advantage insurance (66.2 %). More patients diagnosed in the expanded compared to the initial approval period received PARPi (9.8 % vs. 6.6 %, p &lt; 0.0001) and within less time from diagnosis to PARPi initiation (HR: 2.31, 95 % CI 2.06, 2.59). Age over 65 was associated with lower likelihood of PARPi receipt (OR: 0.85, 95 % CI 0.74, 0.98). In the initial approval period, patients residing in non-white zip codes were more likely to receive a PARPi (OR: 1.61, 95 % CI 1.19, 2.18) and frail patients were less likely to receive a PARPi (OR: 0.41, 95 % CI 0.22, 0.78).</div></div><div><h3>Conclusion</h3><div>Since 2015, PARPi use increased among ovarian cancer patients, and time from diagnosis to PARPi receipt decreased, reflecting expanded PARPi indications over time. Monitoring demographic and clinical characteristics of PARPi recipients may help assess population-level use of novel therapeutics.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"101 ","pages":"Article 102996"},"PeriodicalIF":2.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146025000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Early-onset cancer incidence in the United States by race/ethnicity between 2011 and 2020” [Cancer Epidemiol. 92 (2024) 102632]","authors":"Anjali Gupta ,&nbsp;Tomi Akinyemiju","doi":"10.1016/j.canep.2026.102998","DOIUrl":"10.1016/j.canep.2026.102998","url":null,"abstract":"","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"101 ","pages":"Article 102998"},"PeriodicalIF":2.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146127627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence and survival of head and neck cancers in the United Kingdom 2000–2021","authors":"Andrea Miquel-Dominguez ,&nbsp;Eng Hooi Tan ,&nbsp;Edward Burn ,&nbsp;Antonella Delmestri ,&nbsp;Talita Duarte-Salles ,&nbsp;Asieh Golozar ,&nbsp;Wai Yi Man ,&nbsp;Daniel Prieto-Alhambra ,&nbsp;Francesc Xavier Avilés-Jurado ,&nbsp;Danielle Newby","doi":"10.1016/j.canep.2026.103018","DOIUrl":"10.1016/j.canep.2026.103018","url":null,"abstract":"<div><h3>Background</h3><div>Understanding the changing burden of head and neck cancers (HNC) is essential to guide public health interventions and inform cancer care strategies.</div></div><div><h3>Methods</h3><div>We conducted a cohort study using routinely collected primary care data Clinical Practice Research Datalink (CPRD) GOLD from the United Kingdom. Adults aged ≥ 18 years with ≥ 1 year of prior history were included. We estimated crude and age-standardised incidence rates (IRs) and one-, five-, and ten-year survival from 2000 to 2021, stratified by age and calendar year. Findings from CPRD GOLD were compared with primary care data from CPRD Aurum (England only).</div></div><div><h3>Results</h3><div>There were 12,455 patients with a diagnosis of HNC from CPRD GOLD (69.2 % male; median age 64 years). Crude incidence in GOLD increased from 9.08 (95 % CI: 7.88–10.42) per 100,000 person-years in 2000–15.59 (14.07–17.23) in 2021, with similar trends observed in CPRD Aurum. Age-standardised incidence trends were attenuated overall but remained elevated for oropharyngeal and tongue cancers. Five-year survival improved modestly, from 53.8 % (95 % CI: 51.4–56.3 %) in 2000–2004–58.7 % (56.5–60.9 %) in 2015–2019.</div></div><div><h3>Conclusions</h3><div>Incidence increases for HNC were attenuated after age standardisation, suggesting a contribution of demographic ageing, although elevations persisted for specific subsites. Small improvements in long term survival highlights more research is needed to improve earlier diagnosis which will lead to better patient outcomes.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"101 ","pages":"Article 103018"},"PeriodicalIF":2.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146173872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unicentric retrospective study of gastroenteropancreatic neuroendocrine tumors: Updated epidemiological insights","authors":"Christèle Asmar ,&nbsp;Raphaël Asmar ,&nbsp;Maria Al Rachid ,&nbsp;Carole Kesrouani ,&nbsp;Viviane Trak-Smayra ,&nbsp;Hampig Raphaël Kourié ,&nbsp;Joseph Gharios","doi":"10.1016/j.canep.2026.102988","DOIUrl":"10.1016/j.canep.2026.102988","url":null,"abstract":"<div><h3>Background</h3><div>Neuroendocrine neoplasms (NENs) are rare tumors, making up 0.5 % of all cancers, with around 65 % found in the gastroenteropancreatic (GEP) system, with increasing occurrence globally in recent years. The World Health Organization (WHO) classifies GEP-NENs into two main groups: neuroendocrine tumors and neuroendocrine carcinomas according to the new 2022 classification.</div></div><div><h3>Aim</h3><div>To provide updated epidemiological data on GEP-NENs diagnosed at a tertiary referral center in Beirut, Lebanon, using the WHO 2022 classification, and to describe changes in incidence, demographics, and tumor characteristics compared with previously reported data.</div></div><div><h3>Methods</h3><div>This retrospective study included patients treated at Hotel Dieu de France, from January 2013 to June 2024, with histologically confirmed GEP-NENs and complete medical records available. GEP-NENs were categorized based on their primary site and pathology reports reanalyzed according to the WHO 2022 classification. Data were then collected on patient demographics, primary tumor site, tumor grade and presence of metastasis at diagnosis.</div></div><div><h3>Results</h3><div>Among 194 NENs diagnosed during the study period, 74 were GEP-NENs (25.2 %). The mean age at diagnosis was 59.8 years, with a male-to-female ratio of 1.61. Of patients with available grading data, 39.0 % were classified as NET G1, 34.4 % as NET G2, and 26.6 % as high-grade disease (NET G3 and NEC combined). Compared with data from the previous decade, a lower proportion of G1 tumors and higher proportions of G2 and G3 tumors were observed, along with higher frequencies of pancreatic and hepatic primaries and lower rates of colonic and duodenal primaries. NET G3 and NECs were most frequently located in the liver, ampulla of Vater, and colon. All colorectal GEP-NENs identified were metastatic at diagnosis.</div></div><div><h3>Conclusion</h3><div>GEP-NENs in this cohort were more frequently diagnosed with higher histological grades and metastatic disease compared to the previous decade, a pattern observed during a period marked by major socioeconomic disruption and the COVID-19 pandemic.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"101 ","pages":"Article 102988"},"PeriodicalIF":2.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145981929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Haematological cancer in pregnancy in New South Wales, Australia: A population-based retrospective cohort study","authors":"Tanmay Bagade ,&nbsp;Nadom Safi ,&nbsp;Nada Hamad ,&nbsp;Antoinette Anazodo ,&nbsp;Marc Remond ,&nbsp;Elizabeth Sullivan","doi":"10.1016/j.canep.2026.103020","DOIUrl":"10.1016/j.canep.2026.103020","url":null,"abstract":"<div><h3>Background</h3><div>Pregnancy-associated haematological cancers (PAHC) are rare but may have profound impacts on maternal and neonatal outcomes. We aimed to describe the incidence, survival rates, and perinatal outcomes associated with PAHC in New South Wales (NSW), Australia.</div></div><div><h3>Methods</h3><div>Utilising seven datasets, we performed a population-based retrospective cohort study, linking data for all women who gave birth in NSW from 1994 to 2013, and tracked mortality outcomes up to 2018. Women and their babies were stratified into three groups: gestational haematological cancer (HC), postpartum HC group, and pregnant women not diagnosed with cancer. Descriptive statistics, incidence, mortality rate, survival probability, and a composite severe maternal morbidity outcome indicator (MMOI) and composite neonatal adverse outcome indicator (NAOI) were calculated and compared between groups. We also conducted a sub-group analysis of women with lymphoma and leukaemia.</div></div><div><h3>Findings</h3><div>Of the 1786,302 pregnancies included in the cohort, 224 women were diagnosed with PAHC. The overall incidence of PAHC was 12.5/100,000 women giving birth, which increased by 4 % yearly over the study period. The overall mortality rate was 15.5/1000 and 20/1000 women-years in the gestational HC and postpartum HC groups, respectively. Gestational HCs were associated with higher odds of MMOI (AOR 17.39 (95 % CI: 9.88–30.59) and NAOI (AOR 4.69 (95 % CI: 2.43–9.03) compared to postpartum HC and pregnant women not diagnosed with cancer.</div></div><div><h3>Interpretation</h3><div>Over the two-decade study period, we observed a significant increase in the incidence of PAHCs, with an associated higher maternal and neonatal mortality and morbidity for women with gestational HCs. Our results emphasise the critical importance of decision-making and clinical practice regarding the continuation of pregnancy and cancer management for women diagnosed with PAHCs.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"101 ","pages":"Article 103020"},"PeriodicalIF":2.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146173873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The association between body fatness and prevalent MGUS in the U.S. general population","authors":"Mengmeng Ji ,&nbsp;John H. Huber ,&nbsp;Mei Wang ,&nbsp;Tuo Lan ,&nbsp;Graham A. Colditz ,&nbsp;Shi-Yi Wang ,&nbsp;Su-Hsin Chang","doi":"10.1016/j.canep.2026.103021","DOIUrl":"10.1016/j.canep.2026.103021","url":null,"abstract":"<div><h3>Objective</h3><div>Current evidence regarding the association between obesity and monoclonal gammopathy of undetermined significance (MGUS) remains inconsistent. This study aims to evaluate the relationship between objectively measured obesity markers and prevalent MGUS using nationally representative data from the U.S. population.</div></div><div><h3>Method</h3><div>Data came from the third National Health and Nutrition Examination Survey III (1988–1994) and continuous NHANES (1999–2004). We estimated multivariable-adjusted odds ratios (aORs) and 95 % confidence intervals (CIs) for the association between MGUS and seven obesity markers (i.e., baseline body mass index (BMI), maximum lifetime BMI, waist circumference (WC), waist-hip ratio (WHR), total body fat, fat-free mass, and body fat percentage) using logistic regression. Body composition was assessed using dual-energy X-ray absorptiometry (DXA) in NHANES 1999–2004 and tetrapolar bioelectrical impedance analysis (BIA) in NHANES III.</div></div><div><h3>Results</h3><div>The study included 200 participants with MGUS in NHANES III (1988–1994) and 164 with MGUS in NHANES 1999–2004, compared with 12,043 participants without MGUS. In multivariate logistic regression analysis with DXA measurements, each 1 %age point increase in body fat percentage was associated with a 4 % higher odds of MGUS (aOR: 1.04, 95 % CI [1.01, 1.07]) and a 6 % higher odds of non-IgM MGUS (aOR: 1.06, 95 % CI [1.02, 1.10]). No statistically significant associations were found between MGUS and other obesity markers, including baseline BMI, maximum lifetime BMI, WC, WHR, and fat-free mass.</div></div><div><h3>Conclusion</h3><div>Our findings indicate that obesity is associated with an increased odds of MGUS. However, many obesity markers, including the commonly used BMI, do not adequately capture this association.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"101 ","pages":"Article 103021"},"PeriodicalIF":2.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146215069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}